T
T-CURX
T-CURX – Frontline Cancer Immunotherapy
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Würzburg, Germany
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 87.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Investment activity
- 1 company, latest Jun 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2025 | $20M | $80M | Highlight Capital · BioMedVC · Bayern Kapital · i&i Biotech Fund | ↗ |
Growth signals
Latest recorded traffic for T-CURX is 2.3K monthly website visits, up 109.1% over the last three months. T-CURX's team grew 81.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
BioMedVC
Highlight Capital
Bayern Kapital
i&i Biotech Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about T-CURX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See T-CURX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.